David Quartermain
Overview
Explore the profile of David Quartermain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu P, Li Y, Quartermain D, Boutajangout A, Ji Y
Brain Res
. 2013 Jun;
1522:67-75.
PMID: 23743262
Although the mechanisms underlying mild traumatic brain injury (mTBI) are becoming well understood, treatment options are still limited. In the present study, mTBI was induced by a weight drop model...
2.
Li Y, Shemmer B, Stone E, Nardi M, Jonas S, Quartermain D
Brain Res
. 2013 Mar;
1507:134-45.
PMID: 23473843
Inhaled nitric oxide (iNO) has been shown to reduce ischemia/reperfusion (I/R) injury in several different organ systems including the brain. We investigated whether iNO was neuroprotective in a mouse model...
3.
Boutajangout A, Li Y, Quartermain D, Sigurdsson E
Methods Mol Biol
. 2012 Apr;
849:529-40.
PMID: 22528113
In the last couple of decades, substantial progress has been made in the development of transgenic mouse models developing amyloid-β deposits and/or neurofibrillary tangles. These mouse models of Alzheimer's disease...
4.
Haile M, Galoyan S, Li Y, Cohen B, Quartermain D, Blanck T, et al.
Anesth Analg
. 2012 Feb;
114(5):1034-41.
PMID: 22366846
Background: Acute hypotension may be implicated in cognitive dysfunction. L-type calcium channel blockers in the setting of hypoxia are protective of learning and memory. We tested the hypothesis that hypotension...
5.
Stone E, Lin Y, Sarfraz Y, Quartermain D
Brain Res Rev
. 2011 Feb;
67(1-2):193-208.
PMID: 21315760
Although the central noradrenergic system has been shown to be involved in a number of behavioral and neurophysiological processes, the relation of these to its role in depressive illness has...
6.
Boutajangout A, Quartermain D, Sigurdsson E
J Neurosci
. 2010 Dec;
30(49):16559-66.
PMID: 21147995
Harnessing the immune system to clear protein aggregates is emerging as a promising approach to treat various neurodegenerative diseases. In Alzheimer's disease (AD), several clinical trials are ongoing using active...
7.
Stone E, Lin Y, Sarfraz Y, Quartermain D
Int J Neuropsychopharmacol
. 2010 May;
14(3):319-31.
PMID: 20459885
The present study examined the ability of 6-fluoronorepinephrine (6FNE), a full selective α-adrenoceptor agonist, to produce antidepressant-like effects in mice. The drug, administered in the 4th ventricle, produced marked anti-immobility...
8.
Bekker A, Haile M, Li Y, Galoyan S, Garcia E, Quartermain D, et al.
Anesth Analg
. 2009 Nov;
109(6):1943-8.
PMID: 19923525
Background: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction. We tested the hypothesis that nimodipine (NIMO) administered at the onset...
9.
Boutajangout A, Goni F, Knudsen E, Schreiber F, Asuni A, Quartermain D, et al.
J Alzheimers Dis
. 2009 Sep;
18(4):961-72.
PMID: 19749432
Immunotherapy holds great promise for Alzheimer's disease (AD) and other conformational disorders but certain adverse reactions need to be overcome. Prior to the side effects in the first Elan/Wyeth AD...
10.
Stone E, Lin Y, Sarfraz Y, Quartermain D
Brain Res
. 2009 Jul;
1291:21-31.
PMID: 19632210
alpha(1)-Adrenoceptors are concentrated in the locus coeruleus (LC) where they appear to regulate various active behaviors but have been difficult to stimulate effectively. The present study examined the behavioral, pharmacological...